NeoGenomics, Inc. (NEO) vs Recursion Pharmaceuticals, Inc. (RXRX)
A side-by-side comparison of NeoGenomics, Inc. and Recursion Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 2, 2026. Differences are shown without an overall score or investment verdict.
NEO
NeoGenomics, Inc.
$18.38HealthcareDelayed quote: Oct 2, 2026, 3:40 PM EDT
RXRX
Recursion Pharmaceuticals, Inc.
$4.08HealthcareDelayed quote: Oct 2, 2026, 3:40 PM EDT
Total return — NEO vs RXRX
growth of $100 · dividends reinvested · last 5yNEO -63.1% (-18.1%/yr)RXRX -77.4% (-25.7%/yr)NEO compounded faster over this window
NEO RXRX
NEO vs RXRX: by the numbers
- •RXRX is the larger company ($2.14B vs $472M market cap).
- •Both run net losses; NEO's is the smaller (-6.77% vs -945.92% net margin).
- •RXRX grew revenue faster over the past five years (45.50% vs 9.41% CAGR).
Metrics side by side
Valuation
| Metric | NEO | RXRX |
|---|---|---|
| Forward P/E | 100.61 | N/A |
| P/S ratio | 0.62 | 39.05 |
| P/B ratio | 0.60 | 2.34 |
Profitability
| Metric | NEO | RXRX |
|---|---|---|
| Gross margin | 42.92% | -61.96% |
| Operating margin | -8.63% | -867.87% |
| Net margin | -6.77% | -945.92% |
| ROE | -6.60% | -56.71% |
| ROIC | -5.29% | -49.78% |
Growth (annualized)
| Metric | NEO | RXRX |
|---|---|---|
| Revenue CAGR (5Y) | 9.41% | 45.50% |
| Total return CAGR (5Y) | -18.18% | -28.56% |
Frequently asked
- Which has grown faster, NEO or RXRX?
- Over the past five years, RXRX grew revenue faster — NEO at a 9.41% CAGR versus RXRX at 45.50%.
- How have NEO and RXRX total returns compared?
- Over the past 5 years, NEO delivered -18.18% and RXRX delivered -28.56% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
NeoGenomics ROERecursion Pharmaceuticals ROENeoGenomics operating marginRecursion Pharmaceuticals operating marginNeoGenomics revenue growthRecursion Pharmaceuticals revenue growthNeoGenomics free cash flowRecursion Pharmaceuticals free cash flow
NeoGenomics & Recursion Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 2, 2026.